Effect of Umifenovir in treatment of covid-19

Evaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital Complex

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200523047550N1

Enrollment

Registered

2020-06-06

Start date

2020-04-20

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid 19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Patients with probable or definitive diagnosis of covid 19 and have risk factor who have been treated with hydroxychloroquine also Received 200 mg arbidol capsule e

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with COVID-19 infection based on PCR test for oropharyngeal and nasopharyngeal secretions or specific lung involvement in chest CT Age over 18 years The patient has PO tolerance Gaining conscious satisfaction from the patient or first-degree relatives responsible for the patient No pregnancy and breastfeeding

Exclusion criteria

Exclusion criteria: Alt more than five times normal Renal failure History of any drug allergies Pregnancy and lactation Use of antiarrhythmic drugs

Design outcomes

Primary

Measure	Time frame
Percentage of people improved with arbidol. Timepoint: 5, 7 and 14 days after taking Arbidol. Method of measurement: follow up with phone.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Ghaderkhani

Tehran University of Medical Sciences

sghaderkhani@sina.tums.ac.ir+98 21 6694 7984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026